Jørgen Bjerggaard Jensen
Clinical trials sponsored by Jørgen Bjerggaard Jensen, explained in plain language.
-
New chemo approach may cut bladder cancer return rates
Disease control CompletedThis study tested whether giving a short, intensive course of the chemotherapy drug Mitomycin C before surgery (chemoresection) could lower the chance of bladder cancer coming back, compared to the usual approach of surgery followed by regular chemotherapy instillations into the …
Phase: PHASE4 • Sponsor: Jørgen Bjerggaard Jensen • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New surgical technique could cut bladder cancer recurrence
Disease control CompletedThis study compares two surgical methods for removing non-muscle invasive bladder tumors. The new method removes the tumor in one piece, while the standard method removes it in fragments. Researchers want to see if the one-piece approach leads to better tumor removal and fewer re…
Phase: NA • Sponsor: Jørgen Bjerggaard Jensen • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New urine test could spot bladder cancer early in remote greenland
Diagnosis CompletedThis study tested whether a simple urine test (Xpert Bladder Cancer Detection Test) can accurately detect bladder cancer in people undergoing cystoscopy. Researchers enrolled 127 adults in Greenland, where access to urology services is limited. The goal was to see if the urine te…
Sponsor: Jørgen Bjerggaard Jensen • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
New scan may spare bladder cancer patients from surgery
Diagnosis CompletedThis study tested whether a special type of PET/MR scan (using radioactive water) can accurately tell if bladder cancer has been completely eliminated by chemotherapy. 13 patients with muscle-invasive bladder cancer were scanned before and after chemotherapy, and the results were…
Phase: NA • Sponsor: Jørgen Bjerggaard Jensen • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC